[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-carcinoma-in-situ\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-carcinoma-in-situ":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100587936","rate-of-malignant-transformation-and-clinical-characteristics-among-an-oral-lichen-planus-cohort-a-retrospective-center-experience-100587936",false,"NCT06934863","Rate of Malignant Transformation and Clinical Characteristics Among an Oral Lichen Planus Cohort: a Retrospective Center Experience","Observational Study of an OLP Patients Cohort: Characteristics, Comorbidities, Risk Factors for Malignant Transformation","LPO_CMR","Inclusion Criteria:\n\n* Clinical-histological diagnosis of Oral lichen planus\n* Patients who gave consensus to personal data treatment\n* Minimum 6 months follow-up\n\nExclusion Criteria:\n\n* Patients who did not give consensus to personal data treatment\n* Oral lichenoid lesions\n* Patients with anamnesis of hematopoietic stem cells transplant\n* Patients with a OSCC at the first histological examination (i.e., namely: also OSCC patients with a OLP background were excluded)","ALL",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","The main objective of this paper will be to evaluate the rate of malignant transformation among a cohort of patients affected by oral lichen planus with long-term follow-up. Secondary aims will be to study and describe the characteristics of these patients to identify potential risk factors for malignant transformation, and to evaluate the therapeutic effects and features to OLP drgus.",[24,25,26],"Oral Lichen Planus","Oral Carcinoma","Oral Carcinoma in Situ",[24,28,25,29],"Malignant Transformation","Oral Dysplasia","RECRUITING","2026-05-12",{"date":33,"type":34},"2026-05-14","ACTUAL",{"date":36,"type":34},"2024-01-31",{"date":38,"type":20},"2029-01-31",{"name":40,"class":41},"Catholic University of the Sacred Heart","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100505718","phase-2-a-proof-of-concept-trial-investigating-safety-and-efficacy-of-apg-157-in-oral-dysplasia-100505718","NCT05865028","A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia","Phase II A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia","Inclusion Criteria:\n\n1. Adult patients age \\> 18 years with biopsy-proven moderate to severe oral dysplasia or carcinoma in situ (CIS) and a visible lesion. Sites include all oral cavity as well as oropharyngeal dysplasia that is accessible in the outpatient clinic.\n2. Histologically proven oral cavity or oropharyngeal moderate or severe dysplasia\u002FCIS as diagnosed by standard pathological methods and a visible lesion on oral exam.\n3. Measurable disease - minimum lesion size of 8 x 3 mm before initial biopsy\n4. Willing to provide blood, oral rinse and tissue from diagnostic biopsies\n5. Leukocytes \\>=3,000\u002Fmicroliter\n6. Absolute neutrophil count \\>= 1,000\u002Fmicroliter, Platelets \\>= 100,000\u002Fmicroliter, Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN), aspartate aminotransferase (AST), serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT) and serum glutamic pyruvic transaminase (SGPT) =\\\u003C 1.5 x institutional upper limit of normal (ULN). Exceptions to this Inclusion Criteria can be made if labs are deemed not clinically significant by the principal investigator (PI).\n7. Willing to use adequate contraception, subject or partner has had a vasectomy or partner is using effective birth control or is post-menopausal for the duration of the study.\n8. Able to take oral medication.\n9. Able to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Pregnant women.\n2. Subjects who have had surgery of the oral cavity, teeth, or gums within the previous 8 weeks excluding biopsies and tooth extractions.\n3. Subjects who have had a fracture of the mandible or maxilla within the previous 8 weeks.\n4. Inability to complete enrollment forms due to any mental status or language problems (e.g. dementia, head injury, overall illness).\n5. History of prior head and neck squamous cell carcinomas (HNSCC) unless curatively treated 1 year or more prior.\n6. Use of chemotherapy and\u002For radiation for any malignancy (excluding nonmelanoma skin cancer and cancer confined to organs with removal as only treatment) in the past 2 years.\n7. Subjects with other related diseases or the oral cavity or oropharynx, as determined to be significant by the PI.\n8. History of allergic reactions attributed to compounds of similar chemical composition to Curcumin (turmeric).\n9. Active or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension. Exceptions to this Exclusion Criteria can be made if patient status is deemed not clinically significant by the PI.\n10. Severe thrombocytopenia increasing the risk of biopsy.\n11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.","18 Years",{"count":52,"type":20},32,"INTERVENTIONAL",[55],"PHASE2","The purpose of this study is to assess whether APG-157 can reduce the tumor size in participants with the study disease. Another purpose is to find out about the effects of APG-157 on certain tumor markers and oral rinses in participants with the study disease.",[58,59,26],"Oropharyngeal Dysplasia","Oral Cavity Dysplasia","2026-01-13",{"date":62,"type":34},"2026-01-14",{"date":64,"type":34},"2023-05-24",{"date":66,"type":20},"2028-05-24",{"name":68,"class":41},"Elizabeth J Franzmann"]